Nikola Ptáková

TL;DR: In this paper, the authors used the FusionPlex Solid Tumor kit (ArcherDX) to perform next-generation sequencing on 17 cases of Intraductal Carcinoma (IC) and found that 47% of the cases harbored a fusion involving RET.

TL;DR: It is shown that the ability to discover novel gene variants with next-generation sequencing–based assays has clinical utility in the pathologic classification of fusion gene-associated tumors.

TL;DR: The distinct molecular findings in IC and SDC support that the tumors are separate malignant salivary tumor entities, and the presence of tumor-type–specific NCOA4-RET or TRIM27-RET translocations in a subset of widely invasive carcinomas with intercalated duct-like immunoprofiles suggests that a recharacterization of IC including its redesignation as “intercalatedduct carcinoma, invasive or noninvasive” may be appropriate.

TL;DR: This study describes 12 ALK-RCCs from 8 institutions, with detailed clinical, pathological, immunohistochemical (IHC), fluorescence in situ hybridization (FISH), and next generation sequencing (NGS) analyses, and advocates a routine ALK IHC screening for “unclassifiable RCCs” with heterogeneous features.

TL;DR: A novel finding in this study was the discovery of a VIM-RET fusion in 1 patient with SC of the parotid gland who could possibly benefit from RET-targeted therapy, the first SC-associated translocation with a non-ETV6 5′ fusion partner.